Pharma I - Drug Discovery and Preclinical Development

Course content

This course gives an overview of the pre-clinical phase of discovery and development of medical drugs. The participants will be able to communicate professionally with the various specialist groups within the area of drug development.


The topics taught are:

  • Target finding and translational validation
  • Small-molecule hit identification and lead optimization
  • Peptides and proteins as drugs
  • Non-clinical safety

BRIDGE - Translational Excellence Programme

Learning outcome

Upon completing the course, participants should be able to:


  • Give an overview of the pre-clinical phase of discovery and development of medicines.
  • Identify correct professional terms in drug discovery and pre-clinical development of medicines.
  • List major steps and elements of the pre-clinical drug development process.
  • Outline definitions of key concepts and the fundamentals of the major disciplines in drug discovery and pre-clinical development.



  • Appraise the integration of the various basic disciplines into the process of discovery and pre-clinical development of medicines.
  • Analyse the sequence and flow of the various steps in the process of drug discovery and pre-clinical development.



  • Liaise with all steps of drug discovery and pre-clinical development.
  • Identify critical factors and bottlenecks that influence the pre-clinical drug development process.
  • Promote and state milestones for the progress of the pre-clinical development of a medical product.
  • Communicate professionally with the various specialist groups within the area of development of medicines.

The course is organized with a mix of scientific seminars by invited speakers, including technical lectures about modern technologies.

The first five course days of the Pharma I course corresponds to week 1 of a course in the Professional Master’s Programme “Master of Industrial Drug Development” (MIND), and the MIND and BRIDGE participants are taught together during this week. The 6th course day is only for BRIDGE participants. For the BRIDGE participants, the course includes group project work where the participants will study and describe the discovery of a known drug in an oral presentation in plenum.

The course will end with an evaluation where participants must reflect on course learning outcomes and give feedback for course development.

Course literature will be published on Absalon.

Participants must meet the admission criteria in BRIDGE - Translational Excellence Programme.

Continuous feedback during the course of the semester
Type of assessment
Continuous assessment
Course participation
Type of assessment details
Attendance and active participation, including the project work and participant presentation the last course day.
Exam registration requirements

Participants are automatically registered for the examination upon admission to the BRIDGE - Translational Excellence Programme.

All aids allowed
Marking scale
passed/not passed
Censorship form
No external censorship
Criteria for exam assessment

Active contribution and course participation according to the BRIDGE Guidelines and Practicalities.

Part time Master and Diploma courses

  • Category
  • Hours
  • Lectures
  • 22
  • Preparation
  • 20
  • Project work
  • 8
  • English
  • 50


Course number
Programme level
Part Time Master
See course dates and course programme in Absalon.
15 participants
Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
Contracting department
  • Department of Drug Design and Pharmacology
Contracting faculty
  • Faculty of Health and Medical Sciences
Course Coordinator
  • Anders Bach   (11-647167687576316564666b4376787167316e7831676e)
Saved on the 05-07-2023

Are you BA- or KA-student?

Are you bachelor- or kandidat-student, then find the course in the course catalog for students:

Courseinformation of students